Skip to main content
. 2014 Jul 9;53(10):1347–1355. doi: 10.3109/0284186X.2014.922215

Figure 4.

Figure 4.

Multivariate analysis of survival outcome with respect to tumour TP53 and clinical nodal status (N) in patients with locally advanced breast cancer from the doxorubicin trial (A,B), the FUMI trial (C,D) or the two trials combined (E,F). OS, overall survival (patients with stage IV disease excluded); RFS, recurrence-free survival. Number of patients per group given in parenthesis. Censored values are marked with +.